Literature DB >> 870124

The sympathomimetic activity of fenfluramine hydrochloride on rat vas deferens.

D R Mottram, D Wadhwani.   

Abstract

1. The peripheral, pharmacological effects of the anorexigenic agent, fenfluramine hydrochloride, have been investigated on rat isolated vas deferens. 2. Characteristic spiked contractions were observed within 2 to 3 min after exposure to fenfluramine; these contractions reached a rate of around 13 per min and were of variable height. 3. Pre-treatment of vasa with the indirectly acting sympathomimetic amine, tyramine, greatly reduced both the height and rate of contraction induced by fenfluramine. 4. The uptake inhibitor, desipramine, required a concentration in excess of 10 micronM to affect fenfluramine-induced contractions. Effects of desipramine on fenfluramine contractions were of equal magnitude whether desipramine was administered before fenfluramine or at the height of the fenfluramine-induced contractions. 5. Pre-treatment with debrisoquine (0.5 mM), reduced the contractions in response to fenfluramine over a period of time. 6. Fenfluramine, added to vasa from rats which had been injected intraperitoneally with 5 mg/kg reserpine 24 h and 48 h previously, failed to induce its characteristic contractions. 7. It is concluded that fenfluramine can be classed as an indirectly acting sympathomimetic amine on peripheral adrenergic nerve terminals.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 870124      PMCID: PMC1667758          DOI: 10.1111/j.1476-5381.1977.tb07729.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  Antagonism by methysergide of the 5-hydroxytryptamine-like action of toxic doses of fenfluramine in dogs.

Authors:  S Jespersen; J Scheel-Krüger
Journal:  J Pharm Pharmacol       Date:  1970-08       Impact factor: 3.765

2.  Some cardiovascular and autonomic effects of fenfluramine hydrochloride.

Authors:  I G Sipes; R J Ziance; J P Buckley
Journal:  J Pharmacol Exp Ther       Date:  1971-01       Impact factor: 4.030

3.  Is 5-hydroxytryptamine involved in the mechanism of action of fenfluramine?

Authors:  W H Funderburk; J C Hazelwood; R T Ruckart; J W Ward
Journal:  J Pharm Pharmacol       Date:  1971-06       Impact factor: 3.765

4.  5,6-Dihydroxytryptamine: suppression of the anorexigenic action of fenfluramine.

Authors:  B V Clineschmidt
Journal:  Eur J Pharmacol       Date:  1973-12       Impact factor: 4.432

5.  Dopamine and 5-hydroxytryptamine inhibit feeding in rats.

Authors:  Z L Kruk
Journal:  Nat New Biol       Date:  1973-11-14

6.  Antagonism by protriptyline and desipramine of the response of the vas deferens of the rat to norepinephrine, acetylcholine and potassium.

Authors:  D P Westfall
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

7.  Effect of thymoleptics on fenfluramine-induced depletion of brain serotonin in rats.

Authors:  D Ghezzi; R Samanin; S Bernasconi; G Tognoni; M Gerna; S Garattini
Journal:  Eur J Pharmacol       Date:  1973-11       Impact factor: 4.432

8.  The effects of selective lesioning of brain serotonin or catecholamine containing neurones on the anorectic activity of fenfluramine and amphetamine.

Authors:  R Samanin; D Ghezzi; L Valzelli; S Garattini
Journal:  Eur J Pharmacol       Date:  1972-09       Impact factor: 4.432

9.  Central nervous system effects of fenfluramine hydrochloride.

Authors:  R J Ziance; I G Sipes; W J Kinnard; J P Buckley
Journal:  J Pharmacol Exp Ther       Date:  1972-01       Impact factor: 4.030

10.  Modification of sympathetic function. Indirectly acting sympathomimetic amines.

Authors:  E Muscholl
Journal:  Pharmacol Rev       Date:  1966-03       Impact factor: 25.468

View more
  1 in total

1.  Calcium modulatory properties of 2,6-dibutylbenzylamine (B25) in rat isolated vas deferens, cardiac and smooth muscle preparations.

Authors:  R Pirisino; G Banchelli; G Ignesti; L Mantelli; R Matucci; L Raimondi; F Buffoni
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.